RedIF is formed by Ibero-American researchers working in different lines of investigation in pharmacometrics. To showcase the scientific work of research groups established in Ibero-American institutions whose coordinators are members of RedIF, we are pleased to share selected publications from 2025.
Below are representative works from research groups in Argentina, Brazil, Colombia, Spain, and Uruguay, highlighting the diverse applications of pharmacometrics across the region. One publication per research group has been selected to be featured here.
Argentina
Brstilo L, Ibarra M, Juliá A, Testard J, Salgueiro R, Mendoza A, Pérez C, Licciardone N, Marquet P, Staciuk R, Buontempo F, Schaiquevich P.
British Journal of Clinical Pharmacology, 2025. DOI: 10.1002/bcp.70256
https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70256
Brazil
Physiologically-based pharmacokinetic modeling and simulation for initial dose optimization of levetiracetam in pediatrics
Macente J, Bonan H, Caleffi-Marchesini ER; Pereira LRL, Lima PF, Annaert P; Karel A; Diniz A.
Frontiers in Pharmacology, v. 16, p. 1, 2025. DOI: 10.3389/fphar.2025.1678960
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1678960/full
PBPK/PD model of vancomycin in sepsis: Linking interstitial exposure in perfusion-limited tissues to MRSA infection
Ben Olivo L, Silva de Lemos JL, Jardim Rodrigues V, Batirola Kretschmer D, de Avila Cruz W, Staudt KJ, Annaert P, Verlindo de Araújo BV.
Pharmaceutics 17(9): 1111, 2025. DOI: 10.3390/pharmaceutics17091111
https://doi.org/10.3390/pharmaceutics17091111
Colombia
Novel Methods Developed in Bioequivalence Assays: Patent Review
Correa Barrera BS, Alves IA & Aragón, DM.
AAPS PharmSciTech 26: 91, 2025. DOI: 10.1208/s12249-025-03079-7
https://link.springer.com/article/10.1208/s12249-025-03079-7#citeas
Spain
A physiologically based pharmacokinetic model to describe [89Zr]Zr-DFO-Adalimumab specific activity after intravitreal administration to rats with endotoxin-induced uveitis
Reig-López, J, García-Otero X, Cuquerella-Gilabert M, Bandín-Vilar E, Otero-Espinar FJ, Fernández-Ferreiro A, Mangas-Sanjuán V, Merino V, Aguiar P, Merino-Sanjuán M.
International Journal of Pharmaceutics 20: 125845, 2025. DOI: 10.1016/j.ijpharm.2025.125845
https://www.sciencedirect.com/science/article/pii/S0378517325006829?via%3Dihub
Design Optimization for Developing Population Pharmacokinetic Models in Critically Ill Children: Application to Teicoplanin, Piperacillin and Meropenem
García-Orueta G, Butragueño-Laiseca L, Santiago MJ, Parra-Guillén ZP, Trocóniz IF.
Clinical Pharmacokinetics, Nov 2025. DOI: 10.1007/s40262-025-01594-1.
https://link.springer.com/article/10.1007/s40262-025-01594-1
Uruguay
Simplificación de la posología de dolutegravir en coinfección VIH/TB tratada con rifampicina: análisis mediante modelado farmacocinético de base fisiológica
Chavarría-Rojas M, Leal A, Álvarez L, Cabrera S & Ibarra M.
Revista Colombiana de Ciencias Químico-Farmacéuticas, 54(2): 509–528, 2025. DOI: 10.15446/rcciquifa.v54n2.118462
https://revistas.unal.edu.co/index.php/rccquifa/article/view/118462
Pharmacometrics modeling and simulation to assist phenobarbital dose optimization in dogs
Alvariza S, Ibarra M, Guevara N, Maldonado C, Vázquez M, Feijoó G, Suárez G. Frontiers in Veterinary Science 12: 1644003, 2025. DOI: 10.3389/fvets.2025.1644003.
https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1644003/full
If your RedIF research group has published work in pharmacometrics in 2025 that is not listed here, please contact us through the website’s contact form to have it included.